| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $5.20B | +11.6% |
| Gross profit | $3.61B | — |
| Operating income | $1.10B | — |
| Net income | $1.34B | +99.3% |
| Gross margin | 69.5% | Net margin 25.7% |
| Segment | Revenue | Share |
|---|---|---|
| Interventional Cardiology Therapies | $1.24B | 23.9% |
| Electrophysiology EP | $0.91B | 17.4% |
| Global Endoscopy Endo Reporting Unit | $0.74B | 14.1% |
| Global Urologyand Pelvic Health Reporting Unit | $0.65B | 12.4% |
| Cardiac Rhythm Management | $0.58B | 11.1% |
| Watchman | $0.51B | 9.7% |
| Global Neuromodulation Nm Reporting Unit | $0.32B | 6.1% |
| Interventional Oncology And Embolization | $0.27B | 5.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $1.59B | 30.6% |
| SG&A | $1.78B | 34.2% |
| Tax & other | $-0.24B | -4.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BMY ・ AVGO ・ BR ・ BRO ・ BF.B ・ BLDR ・ BG ・ BXP ・ CHRW ・ CDNS ・ CPT ・ COF
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies